BioNTech SE

NASDAQ:BNTX

Biotechnology

Healthcare
$83.26 -1.52%

-$1.41 today

Market cap
$20.64B
Beta
1.32
P/E (TTM)
-16.2
EPS (TTM)
-$4.93
52W Low $79.52High $124.00

Volume 1.24M

Average 1.11M

BNTX Debt Repayment

Cash used to repay borrowings during the period.

BioNTech SENASDAQ: BNTX

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment turns positive

Q2 FY2026 debt repayment was €32.69M, compared with -€4.18M a year earlier. Trailing-twelve-month debt repayment was €68.06M. Over 3 fiscal years it compounded at -43.2% a year.

Context

  • Debt repayment amounted to 0.4% of revenue in FY2025, down 1.3 pp from a year earlier.
  • Debt repayment grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near €32.69M or moves back toward the trailing-twelve-month quarterly average of €17.02M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
€32.69M-16.0% QoQ
Last fiscal yearDec 2025
-€10.85M-76.4% YoY
LTMJun 2026
€68.06M+862.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+882.2%——
1 year-76.4%——
3-year CAGR-43.2%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

EUR · from the cash flow

Latest · FY2025
(10.85M) EUR
Year-over-year change
+76.4%

Debt Repayment vs competitors

How BNTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +862.0% is the 2nd highest of 5, against a peer median of +54.5%.
  • Debt repayment amounts to 2.6% of revenue for BNTX, versus a peer median of 0.0%.
BNTX Competitors
Debt Repayment for BNTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TGTXTG Therapeutics, Inc.LTM Sep 2026$490.06M USD——54.6%
GMABGenmab A/SLTM Jun 2026$139.31M USD——3.4%
BNTXBioNTech SELTM Jun 2026€68.06M EUR+862.0%-43.2%2.6%
IBRXImmunityBio, Inc.LTM Sep 2026$5.95M USD+12297.9%-78.5%3.3%
INCYIncyte CorporationLTM Jun 2026$4.64M USD+8.9%+16.7%0.1%
IMTXImmatics N.V.LTM Mar 2026€1.47M EUR-55.0%—4.0%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$0 USD——0.0%
XNCRXencor, Inc.LTM Jun 2026$0 USD——0.0%
IMCRImmunocore Holdings plcLTM Mar 2026$0 USD+100.0%—0.0%
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
MGNXMacroGenics, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding BNTX) —+54.5%-30.9%0.0%

Competitors are the stored peer set for BNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income15.05B12.95B1.19B(677.7M)(1.09B)
Depreciation & Amortization75.2M123.3M183.4M298M367.69M
Deferred Income Tax000070.98M
Stock-Based Compensation93.9M108.6M51.4M100.9M0
Change in Working Capital(10.73B)4.52B5.57B1.22B516.57M
Accounts Receivables(11.81B)4.37B5.37B387.7M1.04B
Inventory(438.4M)62.9M81.9M74.5M170.88M
Accounts Payables1.52B85.7M118.9M758.4M(695.23M)
Other Working Capital00000
Other Non-Cash Items(3.6B)(4.13B)(1.62B)(734.1M)574.01M
Operating Cash Flow889.7M13.58B5.37B207.7M438M
Capital Expenditures(154M)(363.3M)(705.5M)(452.3M)(168.19M)
Acquisitions (Net)(20.8M)0(336.9M)0183.27M
Purchases of Investments(394.7M)(47.8M)(6.98B)(12.37B)(10.97B)
Sales of Investments0375.2M1.19B10.74B9.14B
Other Investing Activities(23.1M)(33.5M)(576.59M)(164.6M)0
Investing Cash Flow(566.1M)(35.3M)(6.95B)(2.08B)(2.37B)
Debt Repayment(66.7M)(59.1M)(40.1M)(45.9M)(10.85M)
Common Stock Issued160.9M110.5M000
Common Stock Repurchased0(986.4M)(738.5M)00
Dividends Paid0(484.3M)000
Other Financing Activities0000(39.96M)
Financing Cash Flow94.2M(1.42B)(778.6M)(45.9M)(50.81M)
Effect of Forex Changes64.7M60.1M150.3M14.8M1.05B
Net Change in Cash482.5M12.18B(2.21B)(1.9B)(931.17M)
Free Cash Flow735.7M13.21B4.67B(244.6M)269.81M

BioNTech SE

NASDAQ:BNTX

Intrinsic Alpha fair value

Locked

Current Price

$83.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.